167 related articles for article (PubMed ID: 28648553)
21. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
Demyttenaere K; Hemels ME; Hudry J; Annemans L
Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
[TBL] [Abstract][Full Text] [Related]
22. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
Bech P; Andersen HF; Wade A
Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
[TBL] [Abstract][Full Text] [Related]
23. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
24. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.
Saghafi R; Brown C; Butters MA; Cyranowski J; Dew MA; Frank E; Gildengers A; Karp JF; Lenze EJ; Lotrich F; Martire L; Mazumdar S; Miller MD; Mulsant BH; Weber E; Whyte E; Morse J; Stack J; Houck PR; Bensasi S; Reynolds CF
Int J Geriatr Psychiatry; 2007 Nov; 22(11):1141-6. PubMed ID: 17486678
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of escitalopram and severity of depression: new data].
Spadone C
Encephale; 2009 Dec; 35(6):577-85. PubMed ID: 20004289
[TBL] [Abstract][Full Text] [Related]
26. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
27. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
28. HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients.
Wang P; Lv Q; Mao Y; Zhang C; Bao C; Sun H; Chen H; Yi Z; Cai W; Fang Y
J Affect Disord; 2018 Mar; 228():222-228. PubMed ID: 29275155
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
Llorca PM; Azorin JM; Despiegel N; Verpillat P
Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of escitalopram compared to citalopram: a meta-analysis.
Montgomery S; Hansen T; Kasper S
Int J Neuropsychopharmacol; 2011 Mar; 14(2):261-8. PubMed ID: 20875220
[TBL] [Abstract][Full Text] [Related]
31. [Severe forms of depression: the efficacy of escitalopram].
Spadone C
Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
[TBL] [Abstract][Full Text] [Related]
32. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
Montgomery SA; Möller HJ
Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
[TBL] [Abstract][Full Text] [Related]
33. The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine.
Sun Y; Drevets W; Turecki G; Li QS
Brain Behav Immun; 2020 Jul; 87():404-412. PubMed ID: 31978524
[TBL] [Abstract][Full Text] [Related]
34. Superiority of escitalopram to paroxetine in the treatment of depression.
Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
[TBL] [Abstract][Full Text] [Related]
35. Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study.
Weintraub D; Taraborelli D; Morales KH; Duda JE; Katz IR; Stern MB
J Neuropsychiatry Clin Neurosci; 2006; 18(3):377-83. PubMed ID: 16963587
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Colonna L; Andersen HF; Reines EH
Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
[TBL] [Abstract][Full Text] [Related]
37. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression.
Bech P; Tanghøj P; Cialdella P; Andersen HF; Pedersen AG
Int J Neuropsychopharmacol; 2004 Sep; 7(3):283-90. PubMed ID: 15320956
[TBL] [Abstract][Full Text] [Related]
38. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
Sung SC; Wisniewski SR; Balasubramani GK; Zisook S; Kurian B; Warden D; Trivedi MH; Rush AJ;
Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
[TBL] [Abstract][Full Text] [Related]
39. Patterns of cardiorespiratory coordination in young women with recurrent major depressive disorder treated with escitalopram or venlafaxine.
Chang JS; Ha K; Yoon IY; Yoo CS; Yi SH; Her JY; Ha TH; Park T
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):136-42. PubMed ID: 22699029
[TBL] [Abstract][Full Text] [Related]
40. A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.
Sørensen J; Stage KB; Damsbo N; Le Lay A; Hemels ME
Nord J Psychiatry; 2007; 61(2):100-8. PubMed ID: 17454724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
